Alphamab Oncology Stock
Stocks
9966
KYG0330A1013
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
Hong Kong S.E.
02:32:50 2026-09-15 EDT
|
5-day change | 1st Jan Change | ||
| 7.845 HKD | -2.30% |
|
-5.60% | -19.95% |
| Market Cap | 6.66B 7.78B 992M 859M 811M 736M 1.38B 95.03B 1.39B 9.68B 3.73B 48.21B 3.72B 3.64B 153B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 6.66B 7.78B 992M 859M 811M 736M 1.38B 95.03B 1.39B 9.68B 3.73B 48.21B 3.72B 3.64B 153B | EV / Sales 2026 * |
21.2x | EV / Sales 2027 * | 9.89x |
| Free-Float |
49.42% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Hong Kong S.E.
| 9966 | Delayed | |
OTC Markets
| ALMOF | Delayed | |
|
Tradegate
| 3NK | Real-time | |
|
Deutsche Boerse AG
| 3NK | Delayed | |
|
Börse Stuttgart
| 3NK | Delayed | |
|
Boerse Muenchen
| 3NK | Real-time |
| 1 day | -2.30% | ||
| 1 week | -5.60% | ||
| Current month | -12.49% | ||
| 1 month | -6.05% | ||
| 3 months | +11.91% | ||
| 6 months | -10.85% | ||
| Current year | -19.95% |
| 1 week | 7.8 |  | 8.49 |
| 1 month | 7.8 | | 9.38 |
| Current year | 6.23 | | 12.2 |
| 1 year | 6.23 | | 15.75 |
| 3 years | 2 | | 15.75 |
| 5 years | 2 | | 21.35 |
| 10 years | 2 | | 28.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ting Xu
CEO | Chief Executive Officer | 53 | 2018-09-30 |
Fei Wang
DFI | Director of Finance/CFO | - | 2026-03-15 |
Hongwei Wang
CTO | Chief Tech/Sci/R&D Officer | - | 2026-03-10 |
| Director | Title | Age | Since |
|---|---|---|---|
Ting Xu
CHM | Chairman | 53 | 2018-10-30 |
Yang Liu
BRD | Director/Board Member | 54 | 2018-10-30 |
Dong Wu
BRD | Director/Board Member | 56 | 2019-11-23 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.30% | -5.60% | -36.22% | -14.17% | 992M | |
| +0.56% | -4.71% | -2.45% | +9.18% | 45.63B | |
| +0.66% | -2.34% | +340.62% | +530.14% | 43.96B | |
| +1.49% | -0.78% | +41.90% | +24.75% | 43.73B | |
| +2.11% | -1.24% | +9.09% | +78.25% | 40.23B | |
| +0.34% | -4.03% | +9.34% | +38.90% | 31.86B | |
| +0.53% | -2.08% | - | - | 17.4B | |
| +1.34% | +0.70% | +21.35% | +112.62% | 16.62B | |
| +2.07% | +0.78% | +13.07% | +30.91% | 14.46B | |
| -1.85% | -5.33% | +78.63% | +31.45% | 13.04B | |
| Average | +0.50% | -2.23% | +52.82% | +93.56% | 26.79B | |
| Weighted average by Cap. | +0.93% | -2.03% | +75.41% | +127.38% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 314M 367M 46.76M 40.51M 38.23M 34.69M 65.07M 4.48B 65.54M 457M 176M 2.27B 176M 172M 7.23B | 673M 787M 100M 86.9M 82.01M 74.4M 140M 9.61B 141M 979M 377M 4.88B 377M 368M 15.5B |
| Net income | - | - |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-15 | HK$7.845 | -2.30% | 182,000 |
| 26-09-14 | HK$8.030 | +0.75% | 721,258 |
| 26-09-11 | HK$7.970 | -4.32% | 1,226,000 |
| 26-09-10 | HK$8.330 | -1.42% | 841,000 |
| 26-09-09 | HK$8.450 | +1.68% | 976,000 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- 9966 Stock
Select your edition
All financial news and data tailored to specific country editions
